Precision BioSciences (DTIL) Expected to Announce Earnings on Thursday

Precision BioSciences (NASDAQ:DTIL) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 15th. Analysts expect the company to announce earnings of ($0.38) per share and revenue of $5.00 million for the quarter.

Precision BioSciences (NASDAQ:DTIL) last announced its earnings results on Wednesday, March 26th. The company reported ($3.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.09) by ($1.11). Precision BioSciences had a net margin of 11.48% and a negative return on equity of 23.69%. The company had revenue of $3.47 million during the quarter, compared to analyst estimates of $4.28 million. On average, analysts expect Precision BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Precision BioSciences Stock Down 1.5%

DTIL opened at $5.14 on Wednesday. The company has a market cap of $54.23 million, a PE ratio of 85.68 and a beta of 1.55. Precision BioSciences has a twelve month low of $3.61 and a twelve month high of $13.44. The company has a 50-day moving average price of $5.03 and a 200 day moving average price of $5.55. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Precision BioSciences in a report on Friday, March 28th.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.